Metabolic syndrome is linked to most cancers incidence.
Big data
Early stage of metabolic syndrome
Metabolic syndrome
Most cancers
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
19
08
2024
accepted:
25
09
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
aheadofprint
Résumé
Since many people die of either cancers or cardiovascular diseases worldwide, it is important to find the clinical pitfall that provokes cardiovascular diseases and cancer overall. Since metabolic syndrome (MetS) is largely linked to cardiovascular diseases, we have come to consider that MetS, even in its early state, may prime the occurrence of cancers overall. Indeed, the importance of MetS in causing pancreatic cancer has been proved using our large medical database. We analyzed Japanese healthcare and clinical data in 2005, who were followed up until 2020 and we examined the incidence of major cancers. At the enrollment, we examined the presence or absence of MetS judged by either Japanese criteria or NCEP/ATPIII. Of 2.7 million subjects without missing data, 102,930; 200,231; 237,420; 63,435; 76,172; and 2,422 subjects suffered lung, stomach, colon, liver and prostate cancer, respectively, and myelogenous leukemia during follow-up. MetS, defined by Japanese criteria, increased (p < 0.005 each) the incidence of cancer with a hazard ratio (HR) of 1.03-1.47 for lung, stomach, colon, liver, prostate cancers, and myelogenous leukemia. According to Japanese criteria, cancer incidence in the pre-stage MetS group was comparable to the MetS group. The results were almost identical when we defined MetS using NCEP ATP III. Taken together, we conclude that MetS is linked to majority of cancers.
Identifiants
pubmed: 39384596
doi: 10.1007/s00380-024-02474-7
pii: 10.1007/s00380-024-02474-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Heart Foundation
ID : Grant for Masafumi Kitakaze
Informations de copyright
© 2024. Springer Nature Japan KK, part of Springer Nature.
Références
Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, Donoso-Bach L, Frija G, Hierath M, Holmberg O, Khong PL, Lewis JS, McGinty G, Oyen WJG, Shulman LN, Ward ZJ, Scott AM (2021) Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol 22(4):e136–e172. https://doi.org/10.1016/s1470-2045(20)30751-8
doi: 10.1016/s1470-2045(20)30751-8
pubmed: 33676609
pmcid: 8444235
Woodruff RC, Tong X, Khan SS, Shah NS, Jackson SL, Loustalot F, Vaughan AS (2024) Trends in cardiovascular disease mortality rates and excess deaths, 2010–2022. Am J Prev Med 66(4):582–589. https://doi.org/10.1016/j.amepre.2023.11.009
doi: 10.1016/j.amepre.2023.11.009
pubmed: 37972797
Permuth-Wey J, Egan KM (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8(2):109–117. https://doi.org/10.1007/s10689-008-9214-8
doi: 10.1007/s10689-008-9214-8
pubmed: 18763055
Rebours V, Boutron-Ruault MC, Schnee M, Férec C, Maire F, Hammel P, Ruszniewski P, Lévy P (2008) Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol 103(1):111–119. https://doi.org/10.1111/j.1572-0241.2007.01597.x
doi: 10.1111/j.1572-0241.2007.01597.x
pubmed: 18184119
DiMagno EP, Reber HA, Tempero MA (1999) AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117(6):1464–1484. https://doi.org/10.1016/s0016-5085(99)70298-2
doi: 10.1016/s0016-5085(99)70298-2
pubmed: 10579989
Mack TM, Yu MC, Hanisch R, Henderson BE (1986) Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 76(1):49–60
pubmed: 3455742
Qiu D, Kurosawa M, Lin Y, Inaba Y, Matsuba T, Kikuchi S, Yagyu K, Motohashi Y, Tamakoshi A (2005) Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J Epidemiol 15(Suppl 2):S157-167. https://doi.org/10.2188/jea.15.s157
doi: 10.2188/jea.15.s157
pubmed: 16127228
pmcid: 8639044
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H, Li Z (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer (Oxford, England: 1990) 47(13):1928–1937. https://doi.org/10.1016/j.ejca.2011.03.003
doi: 10.1016/j.ejca.2011.03.003
Miyashita Y, Hitsumoto T, Fukuda H, Kim J, Ito S, Kimoto N, Asakura K, Yata Y, Yabumoto M, Washio T, Kitakaze M (2024) Metabolic syndrome is linked to the incidence of pancreatic cancer. EClinicalMedicine 67:102353. https://doi.org/10.1016/j.eclinm.2023.102353
doi: 10.1016/j.eclinm.2023.102353
pubmed: 38169901
Paku M, Uemura M, Kitakaze M, Miyoshi N, Takahashi H, Mizushima T, Doki Y, Eguchi H (2023) Clinical significance of preoperative and postoperative serum CEA and carbohydrate antigen 19-9 levels in patients undergoing curative resection of locally recurrent rectal cancer. Dis Colon Rectum 66(3):392–400. https://doi.org/10.1097/DCR.0000000000002655
doi: 10.1097/DCR.0000000000002655
pubmed: 36649161
Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA (2022) Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev 38(3):e3502. https://doi.org/10.1002/dmrr.3502
doi: 10.1002/dmrr.3502
pubmed: 34614543
Watanabe J, Kotani K (2020) Metabolic syndrome for cardiovascular disease morbidity and mortality among general Japanese people: a mini review. Vasc Health Risk Manag 16:149–155. https://doi.org/10.2147/vhrm.S245829
doi: 10.2147/vhrm.S245829
pubmed: 32368073
pmcid: 7182458
Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169(5):1505–1522. https://doi.org/10.2353/ajpath.2006.051090
doi: 10.2353/ajpath.2006.051090
pubmed: 17071576
pmcid: 1780220
Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35(11):2402–2411
doi: 10.2337/dc12-0336
pubmed: 23093685
pmcid: 3476894
Yamagishi K, Iso H (2017) The criteria for metabolic syndrome and the national health screening and education system in Japan. Epidemiol Health 39:e2017003. https://doi.org/10.4178/epih.e2017003
doi: 10.4178/epih.e2017003
pubmed: 28092931
pmcid: 5343105
(2001) Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19):2486–2497 https://doi.org/10.1001/jama.285.19.2486
Spector TD, Thompson SG (1991) The potential and limitations of meta-analysis. J Epidemiol Community Health 45(2):89
doi: 10.1136/jech.45.2.89
pubmed: 2072080
pmcid: 1060723
Anazawa T, Miyata H, Gotoh M (2015) Cancer registries in Japan: National Clinical Database and site-specific cancer registries. Int J Clin Oncol 20:5–10
doi: 10.1007/s10147-014-0757-4
pubmed: 25376769
Shen B, Li Y, Sheng C-S, Liu L, Hou T, Xia N, Sun S, Miao Y, Pang Y, Gu K (2023) Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: results from a longitudinal cohort and mendelian randomization study. Lancet Reg Health Western Pac 30:100596
doi: 10.1016/j.lanwpc.2022.100596
Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA (2011) Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54(2):463–471
doi: 10.1002/hep.24397
pubmed: 21538440
Asrih M, Jornayvaz FR (2015) Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link? Mol Cell Endocrinol 418:55–65
doi: 10.1016/j.mce.2015.02.018
pubmed: 25724480
Orabi D, Berger NA, Brown JM (2021) Abnormal metabolism in the progression of nonalcoholic fatty liver disease to hepatocellular carcinoma: mechanistic insights to chemoprevention. Cancers 13(14):3473
doi: 10.3390/cancers13143473
pubmed: 34298687
pmcid: 8307710
Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R (2010) Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24(3):349–358
doi: 10.1016/j.bpg.2010.02.007
pubmed: 20510834
Dhar D, Baglieri J, Kisseleva T, Brenner DA (2020) Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 245(2):96–108. https://doi.org/10.1177/1535370219898141
doi: 10.1177/1535370219898141
pubmed: 31924111
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431
doi: 10.1002/hep.28431
pubmed: 26707365
Nagel G, Stocks T, Späth D, Hjartåker A, Lindkvist B, Hallmans G, Jonsson H, Bjørge T, Manjer J, Häggström C (2012) Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol 91:1519–1531
doi: 10.1007/s00277-012-1489-z
pubmed: 22588328
Ibrahim YH, Yee D (2004) Insulin-like growth factor-I and cancer risk. Growth Hormone IGF Res 14(4):261–269. https://doi.org/10.1016/j.ghir.2004.01.005
doi: 10.1016/j.ghir.2004.01.005
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56(4):549–580. https://doi.org/10.1124/pr.56.4.3
doi: 10.1124/pr.56.4.3
pubmed: 15602010
Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97(1):72–81
doi: 10.1002/ijc.1571
pubmed: 11774246